1. Campbell, G.L.; Hills, S.L.; Fischer, M.; Jacobson, J.A.; Hoke, C.H.; Hombach, J.M.; Marfin, A.A.; Solomon, T.; Tsai, T.F.; Tsu, V.D.; et al. Estimated global incidence of Japanese encephalitis: A systematic review. Bull World Health Organ 2011, 89, 766–774. [CrossRef]
2. Japanese Encephalitis Vaccines. WHO Position Paper—February 2015. Available online: https://apps.who.int/iris/handle/1066 5/242325 (accessed on 20 June 2022).
3. Satchidanandam, V. Japanese encephalitis vaccines. Curr. Treat. Options Infect. Dis. 2020, 12, 375–386. [CrossRef] [PubMed]
4. Hoke, C.H.; Nisalak, A.; Sangawhipa, N.; Jatanasen, S.; Laorakapongse, T.; Innis, B.L.; Kotchasenee, S.; Gingrich, J.B.; Latendresse, J.; Fukai, K.; et al. Protection against Japanese encephalitis by inactivated vaccines. N. Engl. J. Med. 1988, 319, 608–614. [CrossRef] [PubMed]
5. Heffelfinger, J.D.; Li, X.; Batmunkh, N.; Grabovac, V.; Diorditsa, S.; Liyanage, J.B.; Pattamadilok, S.; Bahl, S.; Vannice, K.S.; Hyde, T.B.; et al. Japanese encephalitis surveillance and immunization—Asia and western Pacific regions, 2016. Morb. Mortal Wkly. Rep. 2017, 66, 579–583. [CrossRef] [PubMed]
6. Hills, S.L.; Walter, E.B.; Atmar, R.L.; Fischer, M.; ACIP Japanese Encephalitis Vaccine Work Group. Japanese encephalitis vaccine: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm. Rep. 2019, 68, 1–33. [CrossRef] [PubMed]
7. Arai, S.; Matsunaga, Y.; Takasaki, T.; Tanaka-Taya, K.; Taniguchi, K.; Okabe, N.; Kurane, I. Vaccine Preventable Diseases Surveillance Program of Japan. Japanese encephalitis: Surveillance and elimination effort in Japan from 1982 to 2004. Jpn. J. Infect. Dis. 2008, 61, 333–338. [PubMed]
8. Bhatt, S.; Gething, P.W.; Brady, O.J.; Messina, J.P.; Farlow, A.W.; Moyes, C.L.; Drake, J.M.; Brownstein, J.S.; Hoen, A.G.; Sankoh, O.; et al. The global distribution and burden of dengue. Nature 2013, 496, 504–507. [CrossRef]
9. Thomas, S.J.; Endy, T.P. Current issues in dengue vaccination. Curr. Opin. Infect. Dis. 2013, 26, 429–434. [CrossRef]
10. Thomas, S.J.; Yoon, I.K. A review of Dengvaxia®: Development to deployment. Hum. Vaccin. Immunother. 2019, 15, 2295–2314. [CrossRef]
11. Aguiar, M.; Stollenwerk, N.; Halstead, S.B. The impact of the newly licensed dengue vaccine in endemic countries. PLOS Negl. Trop. Dis. 2016, 10, e0005179. [CrossRef]
12. Hadinegoro, S.R.; Arredondo-García, J.L.; Capeding, M.R.; Deseda, C.; Chotpitayasunondh, T.; Dietze, R.; Muhammad Ismail, H.I.; Reynales, H.; Limkittikul, K.; Rivera-Medina, D.M.; et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N. Engl. J. Med. 2015, 373, 1195–1206. [CrossRef]
13. Halstead, S.B.; O’Rourke, E.J. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J. Exp. Med. 1977, 146, 201–217. [CrossRef]
14. Halstead, S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 2003, 60, 421–467.
15. Pierson, T.C.; Diamond, M.S. Flaviviruses. In Fields Virology, 6th ed.; Knipe, D.M., Howley, P.M., Eds.; Wolters Kluwer Health/Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2013; pp. 747–794.
16. Allison, S.L.; Schalich, J.; Stiasny, K.; Mandl, C.W.; Heinz, F.X. Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J. Virol. 2001, 75, 4268–4275. [CrossRef]
17. Crill, W.D.; Chang, G.J. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J. Virol. 2004, 78, 13975–13986. [CrossRef]
18. Vogt, M.R.; Dowd, K.A.; Engle, M.; Tesh, R.B.; Johnson, S.; Pierson, T.C.; Diamond, M.S. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement- dependent effector mechanisms. J. Virol. 2011, 85, 11567–11580. [CrossRef]
19. Mansfield, K.L.; Horton, D.L.; Johnson, N.; Li, L.; Barrett, A.D.T.; Smith, D.J.; Galbraith, S.E.; Solomon, T.; Fooks, A.R. Flavivirus- induced antibody cross-reactivity. J. Gen. Virol. 2011, 92, 2821–2829. [CrossRef]
20. Calisher, C.H.; Karabatsos, N.; Dalrymple, J.M.; Shope, R.E.; Porterfield, J.S.; Westaway, E.G.; Brandt, W.E. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J. Gen. Virol. 1989, 70, 37–43. [CrossRef]
21. Koraka, P.; Zeller, H.; Niedrig, M.; Osterhaus, A.D.; Groen, J. Reactivity of serum samples from patients with a flavivirus infection measured by immunofluorescence assay and ELISA. Microbes. Infect. 2002, 4, 1209–1215. [CrossRef]
22. Dejnirattisai, W.; Wongwiwat, W.; Supasa, S.; Zhang, X.; Dai, X.; Rouvinski, A.; Jumnainsong, A.; Edwards, C.; Quyen, N.T.H.; Duangchinda, T.; et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 2015, 16, 170–177. [CrossRef]
23. Saito, Y.; Moi, M.L.; Takeshita, N.; Lim, C.K.; Shiba, H.; Hosono, K.; Saijo, M.; Kurane, I.; Takasaki, T. Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults. BMC Infect. Dis. 2016, 16, 578. [CrossRef] [PubMed]
24. Anderson, K.B.; Gibbons, R.V.; Thomas, S.J.; Rothman, A.L.; Nisalak, A.; Berkelman, R.L.; Libraty, D.H.; Endy, T.P. Preexisting Japanese encephalitis virus neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort in Thailand. PLoS Negl. Trop. Dis. 2011, 5, e1311. [CrossRef] [PubMed]
25. Sato, R.; Hamada, N.; Kashiwagi, T.; Imamura, Y.; Hara, K.; Nishimura, M.; Kamimura, T.; Takasaki, T.; Watanabe, H.; Koga, T. Dengue hemorrhagic fever in a Japanese traveler with pre-existing Japanese encephalitis virus antibody. Trop. Med. Health 2015, 43, 85–88. [CrossRef] [PubMed]
26. Chiou, S.S.; Fan, Y.C.; Crill, W.D.; Chang, R.Y.; Chang, G.J. Mutation analysis of the cross-reactive epitopes of Japanese encephalitis virus envelope glycoprotein. J. Gen. Virol. 2012, 93, 1185–1192. [CrossRef]
27. Chiou, S.S.; Crill, W.D.; Chen, L.K.; Chang, G.J. Enzyme-linked immunosorbent assays using novel Japanese encephalitis virus antigen improve the accuracy of clinical diagnosis of flavivirus infections. Clin. Vaccine Immunol. 2008, 15, 825–835. [CrossRef]
28. Chabierski, S.; Barzon, L.; Papa, A.; Niedrig, M.; Bramson, J.L.; Richner, J.M.; Palù, G.; Diamond, M.S.; Ulbert, S. Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion-loop. BMC Infect. Dis. 2014, 14, 246. [CrossRef]
29. Rockstroh, A.; Barzon, L.; Pacenti, M.; Palù, G.; Niedrig, M.; Ulbert, S. Recombinant envelope-proteins with mutations in the conserved fusion loop allow specific serological diagnosis of dengue-infections. PLoS Negl. Trop. Dis. 2015, 9, e0004218. [CrossRef]
30. Crill, W.D.; Hughes, H.R.; Trainor, N.B.; Davis, B.S.; Whitney, M.T.; Chang, G.J. Sculpting humoral immunity through dengue vaccination to enhance protective immunity. Front. Immunol. 2012, 3, 334. [CrossRef]
31. Hughes, H.R.; Crill, W.D.; Chang, G.J. Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement. Virol. J. 2012, 9, 115. [CrossRef]
32. Yamanaka, A.; Konishi, E. Key amino acid substitution for infection-enhancing activity-free designer dengue vaccines. iScience 2019, 13, 125–137. [CrossRef]
33. Richner, J.M.; Himansu, S.; Dowd, K.A.; Butler, S.L.; Salazar, V.; Fox, J.M.; Julander, J.G.; Tang, W.W.; Shresta, S.; Pierson, T.C.; et al. Modified mRNA vaccines protect against Zika virus infection. Cell 2017, 168, 1114–1125.e10. [CrossRef]
34. Yamanaka, A.; Kotaki, T.; Konishi, E. A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity. J. Virol. 2013, 87, 12828–12837. [CrossRef]
35. Tanabayashi, K.; Mukai, R.; Yamada, A.; Takasaki, T.; Kurane, I.; Yamaoka, M.; Terazawa, A.; Konishi, E. Immunogenicity of a Japanese encephalitis DNA vaccine candidate in cynomolgus monkeys. Vaccine 2003, 21, 2338–2345. [CrossRef]
36. Ishikawa, T.; Konishi, E. Mosquito cells infected with Japanese encephalitis virus release slowly-sedimenting hemagglutinin particles in association with intracellular formation of smooth membrane structures. Microbiol. Immunol. 2006, 50, 211–223. [CrossRef]
37. Kotaki, T.; Kurosu, T.; Grinyo-Escuer, A.; Davidson, E.; Churrotin, S.; Okabayashi, T.; Puiprom, O.; Mulyatno, K.C.; Sucipto, T.H.; Doranz, B.J.; et al. An affinity-matured human monoclonal antibody targeting fusion loop epitope of dengue virus with in vivo therapeutic potency. Sci. Rep. 2021, 11, 12987. [CrossRef]
38. Konishi, E.; Yamaoka, M.; Khin-Sane-Win Kurane, I.; Mason, P.W. Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. J. Virol. 1998, 72, 4925–4930. [CrossRef]
39. Kotaki, T.; Yamanaka, A.; Konishi, E.; Kameoka, M. A potent neutralizing mouse monoclonal antibody specific to dengue virus type 1 Mochizuki strain recognized a novel epitope around the N-67 glycan on the envelope protein: A possible explanation of dengue virus evolution regarding the acquisition of N-67 glycan. Virus Res. 2021, 294, 198278.
40. Sjatha, F.; Takizawa, Y.; Kotaki, T.; Yamanaka, A.; Konishi, E. Comparison of infection- neutralizing and -enhancing antibody balance induced by two distinct genotype strains of dengue virus type 1 or 3 DNA vaccines in mice. Microbes. Infect. 2013, 15, 828–836. [CrossRef]
41. Konishi, E.; Tabuchi, Y.; Yamanaka, A. A simple assay system for infection-enhancing and -neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells. J. Virol. Methods 2010, 163, 360–367. [CrossRef]
42. Yamanaka, A.; Imad, H.A.; Phumratanaprapin, W.; Phadungsombat, J.; Konishi, E.; Shioda, T. Antibody-dependent enhancement representing in vitro infective progeny virus titer correlates with the viremia level in dengue patients. Sci. Rep. 2021, 11, 12354. [CrossRef]
43. Vaughn, D.W.; Green, S.; Kalayanarooj, S.; Innis, B.L.; Nimmannitya, S.; Suntayakorn, S.; Endy, T.P.; Raengsakulrach, B.; Rothman, A.L.; Ennis, F.A.; et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 2000, 181, 2–9. [CrossRef]
44. Finkelman, F.D.; Holmes, J.; Katona, I.M.; Urban, J.F., Jr.; Beckmann, M.P.; Park, L.S.; Schooley, K.A.; Coffman, R.L.; Mosmann, T.R.; Paul, W.E. Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 1990, 8, 303–333. [CrossRef]
45. Stavnezer, J.; Amemiya, C.T. Evolution of isotype switching. Semin Immunol. 2004, 16, 257–275. [CrossRef]
46. Yun, S.I.; Lee, Y.M. Japanese encephalitis: The virus and vaccines. Hum. Vaccin. Immunother. 2014, 10, 263–279. [CrossRef]
47. Dejnirattisai, W.; Jumnainsong, A.; Onsirisakul, N.; Fitton, P.; Vasanawathana, S.; Limpitikul, W.; Puttikhunt, C.; Edwards, C.; Duangchinda, T.; Supasa, S.; et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010, 328, 745–748, Erratum in Science 2010, 329, 142. [CrossRef]
48. Li, G.; Jin, H.; Nie, X.; Zhao, Y.; Feng, N.; Cao, Z.; Tan, S.; Zhang, B.; Gai, W.; Yan, F.; et al. Development of a reverse genetics system for Japanese encephalitis virus strain SA14-14-2. Virus Genes 2019, 55, 550–556. [CrossRef]
49. Tang, C.T.; Li, P.C.; Liu, I.J.; Liao, M.Y.; Chiu, C.Y.; Chao, D.Y.; Wu, H.C. An epitope- substituted DNA vaccine improves safety and immunogenicity against dengue virus type 2. PLoS Negl. Trop. Dis. 2015, 9, e0003903. [CrossRef]
50. Wahala, W.M.P.B.; Kraus, A.A.; Haymore, L.B.; Accavitti-Loper, M.A.; de Silva, A.M. Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody. Virology 2009, 392, 103–113. [CrossRef] [PubMed]
論文の公開元へ
